Abcam plc, of Cambridge, U.K., purchased the gene editing platform and oncology product portfolio of Milpitas, Calif.-based Applied Stemcell Inc. for life science research and diagnostic markets. The transaction closed on Jan. 28. No financial details were disclosed.
Best Medical International, of Springfield, Va., and Best Particle Therapy of Teambest Companies entered a memorandum of understanding with the University of Wisconsin Medical Radiation Research Center. Best Particle Therapy will be introducing its 400 MeV ion Rapid Cycling Medical Synchrotron with variable energy, heavy ion treatment technologies, offering proton-to-carbon heavy ion.
Biofourmis, of Boston, and ImagineMIC, of Poughkeepsie, N.Y., revealed a partnership agreement intended to drive improved outcomes and lower health care costs for patients with chronic conditions. The first phase of the collaboration includes integrating Biofourmis' artificial intelligence-powered, FDA-cleared Rhythmanalytics with ImagineMIC's remote management technology, which is monitored by clinicians located in the ImagineMIC Monitoring Intervention Center (MIC).
Conmed Corp., of Utica, N.Y., said it is transferring the listing of its common stock to the New York Stock Exchange (NYSE) from the Nasdaq Global Market. The company expects to begin trading on the NYSE effective at the open of markets Feb. 10. Its shares will continue to trade under the ticker CNMD as part of the transfer to the NYSE.
Curetis GmbH, of Holzgerlingen, Germany, said that Ares Genetics GmbH, a Curetis Group company, and the Chinese genomics company Bgi Group will collaborate in making molecular testing for the new coronavirus 2019-nCoV available in Europe.
Fuzionaire Diagnostics Inc., of Pasadena, Calif., is teaming up with McGill University and Montreal Neurological Institute-Hospital, familiarly known as The Neuro, to develop radiopharmaceuticals for Alzheimer’s disease and Parkinson’s disease. The collaboration will leverage Fuzionaire’s radiopharmaceutical discovery platform with the nuclear medicine and imaging capabilities at McGill and The Neuro to develop new diagnostics and treatments for neurodegenerative diseases.
New York-based Healthfirst Inc. and Nationshearing LLC, of Plantation, Fla., are partnering to expand access to hearing tests and offer lower-priced hearing aids for Healthfirst Medicare Advantage plan members. Starting this month, all eligible plan members will be able to access Nationshearing’s network of hearing aid-related and hearing services, including testing for hearing loss.
Redmond, Wash.-based Microsoft Corp. has committed $40 million AI for Health, a five-year program to promote research and public health efforts that leverage artificial intelligence to improve peoples’ health. The initiative, part of the $165 million Microsoft for Good program, will focus on three key areas: speeding research on prevention, diagnosis and treatment of diseases; increasing global insights on mortality and longevity; and reducing health inequity and improving access to care for underserved populations.
Transenterix Inc., of Research Triangle Park, N.C., reported an agreement with Kitakyushu General Hospital in Fukuoka, Japan, to lease its Senhance digital laparoscopy system.